I too have stated many times my #1 concern is completion of enrollment of the Combo Trial and injection of first patient Mono Trial. IMO the SP is indicative of investor confidence in completing enrollment. Nader's justification was the face to face with the FDA to reduce # of patients from 300 to 150 to 30. The issue is enrollment was frozen while that was negotiated. We lost over a year but could argue we now have gained it back because the decrease from 300 to 30 was hopefully worth that year when enrollment would have continued. The other hurdle is 300 patients is still required for safety data although the FDA is likely to cut that number down if interim data is really strong.
All and all this is a case of investors seeing timelines delayed. Delays are like poison with an investment like this in terms of SP. Add the cumulation of all the shares that were purchased at .75 over the last 3 years through the private offerings and shares are going to be dumped and the warrants retained. The first raise I participated in was at .65 and warrants at .75. That was oversubscribed so we all got cut back. I believe it was 14 million shares and 7 million warrants. Like you said announce the last patient injected Combo and first patient injected Mono and things will change. Things will really change if the Mono Trial enrolls rapidly. I'm not concerned about the results just getting these trials enrolled. Your right about patience...if you don't have a lot of it get out. I'm long and staying until this company is purchased.
News 
Market Data 
Discover 
